JOHN HOBBS: Open Payments
NPI 1164429072 · LEXINGTON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$519 in 35 payments from 14 companies in 2025. Trend: 2023 $1,204 · 2024 $1,045 · 2025 $519
Food & beverage: $519
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $160 |
| Lilly USA, LLC | 3 | $51 |
| Sumitomo Pharma America, Inc. | 3 | $48 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $44 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $32 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $30 |
| AstraZeneca Pharmaceuticals LP | 2 | $29 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| Abbott Laboratories | 1 | $19 |
Products named: VRAYLAR, JARDIANCE, GEMTESA, MOUNJARO, Kerendia, CAPLYTA, AIRSUPRA, Auvelity.
Industry payments across KY — which companies pay providers there.
